Skip to main content

Advertisement

Table 1 Studies Reporting Overall Mortality Data for Delayed Appropriate Therapy of Infections Due to Klebsiella pneumoniae or Escherichia coli

From: A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long?

Author, Year Time Point for DAT, h Pathogen Resistance Status Therapy Type Infection Type n/N Mortality Rate, %
Abhilash et al., 2010 [12] 48 K. pneumoniae or E. coli 73.3% ESBL producing Appropriate Bacteremia; primary sources: UTI, intra-abdominal, pneumonia 17/74 23.0
DAT 16/57 28.1
Anderson et al., 2006 [13] 72 K. pneumoniae 7.7% CAZ-R (of which 85% ESBL producers) Appropriate Bacteremia 12/38 31.6
DAT 14/22 63.6
Daikos et al., 2009 [11] NR K. pneumoniae 41.4% VPKP (of which 20.9% CRE) Appropriate Bacteremia 23/137 16.8
DAT 8/25 32.0
Du et al., 2002 [14] NR K. pneumoniae or E. coli 27% ESBL producers Appropriate Bacteremia 14/71 19.7
DAT 7/14 50.0
Gransden et al., 1990 [15] 48 E. coli NR Appropriate Bacteremia; primary source: UTI, othera 109/659 16.5
DAT 36/132 27.3
Jung et al., 2012 [16] NR K. pneumoniae 3.3% ESBL producers Appropriate Bacteremia; primary source: UTI, otherb 82/500 16.4
DAT 15/54 27.8
Kang et al., 2004 [17] 24 K. pneumoniae 100% ESBL producers (study-selected) Appropriate Bacteremia; primary source: pancreatobiliary tract, liver, pneumonia, UTI, peritonitis 7/33 21.2
DAT 3/14 21.4
24 E. coli Appropriate 2/25 8.0
DAT 4/23 17.4
Kang et al., 2013 [18] 72 E. coli 100% ESBL producers (study-selected) Appropriate Bacteremia; primary source: bacteremia, UTI, biliary tract, intra-abdominal, pneumonia 3/28 10.7
DAT 7/64 10.9
Kim et al., 2002 [19] 72 K. pneumoniae 27.2% ESBL producers Appropriate Bacteremia; primary source: bacteremia, biliary, pneumonia, UTI, liver, peritonitis 5/19 26.3
DAT 5/24 20.8
Lee et al., 2012 [30] NR K. pneumoniae or E. coli 100% ESBL producers (study-selected) Appropriate Bacteremia; primary source: pneumonia, urosepsis, otherc 25/230 10.9
DAT 8/21 38.1
Metan et al., 2005 [20] NR E. coli 100% ESBL producers (study-selected) Appropriate Bacteremia; primary source: pneumonia, UTI, pancreaticobiliary tract, post-surgical wound, cellulitis, abdominal abscess 12/45 26.7
DAT 2/8 25.0
Micek et al., 2010 [21] 24 E. coli 3% ESBL producers Appropriate Bacteremia; primary source: lungs, UTI, central venous catheter, intra-abdominal 60/188 31.9
DAT 11/37 29.7
24 K. pneumoniae 8.5% ESBL producers Appropriate 47/129 36.4
DAT 15/30 50.0
Ortega et al., 2011 [22] NR K. pneumoniae 12% CTX-R Appropriate Bacteremia; primary source: UTI, biliary, catheter-related, pneumonia, abdomen, skin and soft tissue 82/824 10.0
  DAT 14/86 16.3
Park et al., 2011 [23] 24 E. coli 100% ESBL producers (study-selected) Appropriate Bacteremia; primary source: UTI, intra-abdominal; hepatobiliary; skin and soft tissue 10/108 9.3
DAT 7/42 16.7
Rodriguez-Bano et al., 2010 [24] 24 E. coli 100% ESBL producers (study-selected) Appropriate Bacteremia; primary source: UTI, intra-abdominal, respiratory tract 16/53 30.2
DAT 13/43 30.2
Schiappa et al., 1996 [25] 72 K. pneumoniae or E. coli 100% CAZ-R (study-selected) Appropriate Bacteremia 1/19 5.3
DAT 5/12 41.7
Tuon et al., 2011 [26] 48 K. pneumoniae 60% ESBL producers Appropriate Bacteremia 28/55 50.9
DAT 20/49 40.8
Wang et al., 2011 [27] NR K. pneumoniae or E. coli 100% ESBL producers (study-selected) Appropriate Bacteremia; primary source: pneumonia, urosepsis, intra-abdominal, bacteremia, vascular catheter-related, skin and soft tissue 12/50 24.0
DAT 15/63 23.8
Wu et al., 2012 [28] 48 E. coli 100% ESBL producers (study-selected) Appropriate Bacteremia; primary source: urinary tract, intra-abdominal, bacteremia 4/24 16.7
DAT 9/38 23.4
Zarkotou et al., 2011 [29] 24 K. pneumonia 100% KPC producers (study-selected) Appropriate Bacteremia; primary source: central venous catheter, respiratory tract, UTI, skin or soft tissue, central nervous system 5/14 35.7
DAT 13/39 33.3
  1. CAZ-R ceftazidime-resistant, CRE carbapenem-resistant Enterobacteriaceae, CTX-R cefotaxime resistant, DAT delayed appropriate therapy, E. coli Escherichia coli, ESBL extended-spectrum beta lactamase, KPC K. pneumoniae carbapenemase, K. pneumoniae Klebsiella pneumoniae, NR not reported, UTI urinary tract infection, VPKP VIM-1-producing K. pneumoniae
  2. aBiliary tract, intestine, genital tract, bone/joint, meninges, respiratory tract, endocardium, skin/soft tissue, wound
  3. bPeritoneum, pancreatobiliary tract, liver, lung, skin and soft tissue, bone, central nervous system
  4. cVascular catheter-related infection, intra-abdominal, bacteremia, skin and soft tissue